A Phase III Extension Trial With a 1-Arm Crossover From Leuprolide to Degarelix: Comparison of Gonadotropin-Releasing Hormone Agonist and Antagonist Effect on Prostate Cancer

2011 ◽  
Vol 186 (3) ◽  
pp. 889-897 ◽  
Author(s):  
E. David Crawford ◽  
Bertrand Tombal ◽  
Kurt Miller ◽  
Laurent Boccon-Gibod ◽  
Fritz Schröder ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Gonadotropin Releasing Hormone ◽  
Phase Iii ◽  
Releasing Hormone ◽  
Gonadotropin Releasing Hormone Agonist ◽  
Agonist And Antagonist ◽  
Extension Trial ◽  
Antagonist Effect

scholarly journals Effects of androgen suppression by gonadotropin-releasing hormone agonist and flutamide on lipid metabolism in men with prostate cancer: focus on lipoprotein(a)

1996 ◽  
Vol 42 (8) ◽  
pp. 1176-1181 ◽  
Author(s):  
L Denti ◽  
G Pasolini ◽  
P Cortellini ◽  
S Ferretti ◽  
L Sanfelici ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cluster Analysis ◽  
Gonadal Hormones ◽  
Gonadotropin Releasing Hormone ◽  
Cross Sectional ◽  
Releasing Hormone ◽  
Lipoprotein A ◽  
Gonadotropin Releasing Hormone Agonist ◽  
Androgen Suppression ◽  
Clear Relation

Abstract No clear relation between lipoprotein(a) [Lp(a)] and endogenous gonadal hormones has been demonstrated. In this study, we compared the effects on Lp(a) of pharmacological castration in 50 patients with prostate cancer who were undergoing therapy with a gonadotropin-releasing hormone agonist (goserelin), with effects on 58 age-matched controls. We also studied 16 untreated patients under baseline conditions and after 3 months of therapy with goserelin alone or combined with an antiandrogen (flutamide). Neither cross-sectional nor prospective studies showed any significant effects of therapy on Lp(a). However, cluster analysis identified a subgroup of patients showing slight but significant increases in Lp(a) concentrations, as well as greater declines of testosterone and estradiol, suggesting that androgen, like estrogen, can exert some slight, though not easily detectable, influence on Lp(a).

Nutritional and metabolic effects of gonadotropin-releasing hormone agonist treatment for prostate cancer

Metabolism ◽  
1990 ◽  
Vol 39 (12) ◽  
pp. 1314-1319 ◽  
Author(s):  
John A. Tayek ◽  
David Heber ◽  
Lauri O. Byerley ◽  
Barbara Steiner ◽  
Jacob Rajfer ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Gonadotropin Releasing Hormone ◽  
Metabolic Effects ◽  
Releasing Hormone ◽  
Gonadotropin Releasing Hormone Agonist
Sign in / Sign up

Export Citation Format

Share Document